Equity Profile

BDX

Becton, Dickinson and Company

Health CareHealth Care Equipment$41.7B

May7Thu

Post-Earnings Recap

ReportedQ2-2026Pre-Market6:30 AM EDT

Becton, Dickinson and Company Beats on EPS, Stock Up 5.87%

Metric	Actual	Expected	Surprise
EPS	$2.90	$2.78	+4.73%
Revenue	—	$4.7B	—

management commentary, guidance changes, and full analysis available with Pro.

Becton, Dickinson and Company Beats on EPS, Stock Up 5.87%

Key Numbers

Metric	Actual	Expected	Surprise
EPS	$2.90	$2.78	+4.73%
Revenue	—	$4.7B	—

Management Commentary

Tone: Unknown

No transcript is on record, and the analysis is based on numerical results only.

What It Means

Becton, Dickinson's earnings report showed a positive surprise in EPS, which likely contributed to the stock's 5.87% increase. Investors may view the EPS beat as a sign of strong performance, even though revenue details were not disclosed. The lack of guidance may leave some investors cautious about future expectations.

Company Snapshot

Becton, Dickinson and Company (BDX) is a leading global medical technology company that develops and manufactures a wide range of medical devices, instrument systems, and reagents. As a key player in the health care sector, BDX's products are essential for hospitals and laboratories, especially in areas like diagnostics, medication management, and infection prevention.

Key Metrics to Watch

EPS

Earnings per share is a critical measure of profitability and will indicate how well the company is managing costs and generating profit.

$2.78

Revenue

Revenue growth is vital for assessing the company's market demand and overall business health.

$4.7B

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+4.98%

Avg Stock Reaction

-1.31%

Last Quarter Recap

In Q1-2026, BDX reported an EPS of $2.91, exceeding analyst expectations by 3.34%. However, the stock fell by 1.25% the following day, indicating mixed investor sentiment despite the earnings beat.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts are generally optimistic about BDX's upcoming earnings, expecting a solid EPS of $2.78 and revenue of $4.7B. The company has a strong track record of beating earnings estimates, which could influence market reactions.

Bull Case

If BDX continues its trend of exceeding earnings expectations, it could lead to a positive market reaction, especially if management provides strong guidance for future growth.

Bear Case

Conversely, if the company fails to meet expectations or provides cautious guidance, it could lead to a significant drop in stock price, especially given the recent mixed reactions to earnings beats.

Key Metrics to Watch

EPS

$2.78

Earnings per share is a critical measure of profitability and will indicate how well the company is managing costs and generating profit.

Revenue

$4.7B

Revenue growth is vital for assessing the company's market demand and overall business health.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will BDX's EPS exceed the consensus estimate of $2.78?

A beat on EPS could reinforce investor confidence and lead to a positive stock reaction, given the company's history of surpassing earnings expectations.

What guidance will management provide regarding revenue growth?

Investors will closely watch for any indications of future revenue performance, as this could significantly impact stock sentiment.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate BDX's ability to leverage recent innovations in medical technology, which could drive higher-than-expected revenue growth.

Supporting Evidence

BDX has consistently beaten EPS estimates in the past, indicating strong operational performance.

Recent trends in health care spending suggest increased demand for BDX's products, which may not be fully reflected in current estimates.

Key Risk

If BDX's revenue growth exceeds expectations due to strong demand, it could significantly alter market perceptions.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is critical as it will test the company's ability to maintain growth amidst market challenges.

Bull Confirmed If

An EPS of $2.80 or higher, coupled with positive revenue growth guidance, would confirm the bull case.

Bear Confirmed If

An EPS below $2.76 or disappointing revenue guidance would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±6.5%

Historical Avg

±5.4%

Pricing rich

The options market is pricing in a potential move of about 6.5% in either direction following the earnings report, suggesting that traders expect volatility.

Options are pricing ±7.7% while BDX has averaged ±5.4% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

20.2%

Calls (6K)P/C Ratio: 0.47Puts (20K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If BDX beats expectations, history suggests a potential stock increase of around 1.69%, confirming the company's strong performance.

In-Line / Cautious

If results are in line with expectations but management provides cautious commentary, the stock may react neutrally, reflecting uncertainty.

Miss

A miss could lead to a decline, with historical patterns indicating a potential drop of around 1.69%.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

0 buys·1 sell

Members

House only

Est. Notional

$15,001.00–$50,000.00

disclosed dollar ranges

Most Active Members

R-OKKevin HernRep.
1

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches or innovations in the pipeline.
2Details on cost management strategies and their impact on margins.
3Insights into market demand trends for BDX's key product lines.
4Management's outlook on the competitive landscape in the health care equipment sector.
5Any commentary on regulatory changes that could affect operations.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

May4

NCLHReported

Norwegian Cruise Line Holdings Ltd.

RecapView

May4

AXSMReported

Company Snapshot

Key Metrics to Watch

EPS

Earnings per share is a critical measure of profitability and will indicate how well the company is managing costs and generating profit.

$2.78

Revenue

Revenue growth is vital for assessing the company's market demand and overall business health.

$4.7B

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+4.98%

Avg Stock Reaction

-1.31%

Last Quarter Recap

In Q1-2026, BDX reported an EPS of $2.91, exceeding analyst expectations by 3.34%. However, the stock fell by 1.25% the following day, indicating mixed investor sentiment despite the earnings beat.

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If BDX continues its trend of exceeding earnings expectations, it could lead to a positive market reaction, especially if management provides strong guidance for future growth.

Bear Case

Conversely, if the company fails to meet expectations or provides cautious guidance, it could lead to a significant drop in stock price, especially given the recent mixed reactions to earnings beats.

Key Metrics to Watch

EPS

$2.78

Earnings per share is a critical measure of profitability and will indicate how well the company is managing costs and generating profit.

Revenue

$4.7B

Revenue growth is vital for assessing the company's market demand and overall business health.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will BDX's EPS exceed the consensus estimate of $2.78?

A beat on EPS could reinforce investor confidence and lead to a positive stock reaction, given the company's history of surpassing earnings expectations.

What guidance will management provide regarding revenue growth?

Investors will closely watch for any indications of future revenue performance, as this could significantly impact stock sentiment.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate BDX's ability to leverage recent innovations in medical technology, which could drive higher-than-expected revenue growth.

Supporting Evidence

BDX has consistently beaten EPS estimates in the past, indicating strong operational performance.

Recent trends in health care spending suggest increased demand for BDX's products, which may not be fully reflected in current estimates.

Key Risk

If BDX's revenue growth exceeds expectations due to strong demand, it could significantly alter market perceptions.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is critical as it will test the company's ability to maintain growth amidst market challenges.

Bull Confirmed If

An EPS of $2.80 or higher, coupled with positive revenue growth guidance, would confirm the bull case.

Bear Confirmed If

An EPS below $2.76 or disappointing revenue guidance would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±6.5%

Historical Avg

±5.4%

Pricing rich

The options market is pricing in a potential move of about 6.5% in either direction following the earnings report, suggesting that traders expect volatility.

Options are pricing ±7.7% while BDX has averaged ±5.4% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

20.2%

Calls (6K)P/C Ratio: 0.47Puts (20K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If BDX beats expectations, history suggests a potential stock increase of around 1.69%, confirming the company's strong performance.

In-Line / Cautious

If results are in line with expectations but management provides cautious commentary, the stock may react neutrally, reflecting uncertainty.

Miss

A miss could lead to a decline, with historical patterns indicating a potential drop of around 1.69%.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

0 buys·1 sell

Members

House only

Est. Notional

$15,001.00–$50,000.00

disclosed dollar ranges

Most Active Members

R-OKKevin HernRep.
1

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches or innovations in the pipeline.
2Details on cost management strategies and their impact on margins.
3Insights into market demand trends for BDX's key product lines.
4Management's outlook on the competitive landscape in the health care equipment sector.
5Any commentary on regulatory changes that could affect operations.